Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationships
{{output}}
Rationale: The introduction of Pluvicto® ([177Lu]Lu-vipivotide tetraxetan; [177Lu]Lu-PSMA-617) marks a milestone in radioligand therapy (RLT) for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). While dose escalation of [177Lu]Lu-PSMA-61... ...
